• Open Access

GAP161 targets and downregulates G3BP to suppress cell growth and potentiate cisplaitin-mediated cytotoxicity to colon carcinoma HCT116 cells

Authors

  • Hao Zhang,

    1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    Search for more papers by this author
    • These authors contributed equally to this work. [Correction added on 30 August 2012, after first online publication: An equal contribution statement and a second correspondence email have been added.]

  • Shenghua Zhang,

    1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    Search for more papers by this author
    • These authors contributed equally to this work. [Correction added on 30 August 2012, after first online publication: An equal contribution statement and a second correspondence email have been added.]

  • Hongwei He,

    1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    Search for more papers by this author
  • Wuli Zhao,

    1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    Search for more papers by this author
  • Jianhua Chen,

    Corresponding author
    1. Wuhan KatyGen Pharmaceuticals, Wuhan, China
    • Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    Search for more papers by this author
  • Rong-guang Shao

    Corresponding author
    • Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    Search for more papers by this author

To whom correspondence should be addressed.

E-mails: shaor@bbn.cn; chenjianhua@katygenpharma.com

Abstract

Ras-GTPase-activating protein SH3 domain-binding proteins (G3BP) are overexpressed in various human tumors and participate in several signaling pathways involved in growth, differentiation and apoptosis. G3BP interact with RasGAP (Ras-GTPase activating protein) only in growing cells and depend on Ras activation, and participate in the Ras signal pathway. Therefore, the blockage and downregulation of G3BP may be a new strategy for cancer therapy. In this report, we demonstrate that a novel peptide GAP161 blocked the functions of G3BP and markedly suppressed HCT116 cell growth through the induction of apoptosis. The peptide bound with G3BP, which interfered with the interaction of G3BP1 with RasGAP and further suppressed Ras signaling pathways. GAP161 downregulated G3BP1 and G3BP2 proteins. Similarly, the knockdown of G3BP substantially decreased the proliferation of HCT116 cells and inhibited Ras signal pathways. Furthermore, the downregulation of G3BP could enhance cisplatin-induced apoptosis and growth inhibition of HCT116 cells. We also found that GAP161 suppressed the growth of BALB/c mice bearing colon CT26 tumors and nude mice bearing HCT116 xenografts. These results suggest that downregulation of G3BP might be useful in cancer therapy and that GAP161 is a promising new therapeutic agent for cancers. (Cancer Sci, doi: 10.1111/j.1349-7006.2012.02361.x, 2012)

Ancillary